Medication-related Osteonecrosis of the Lower Jaw Without Osteolysis on Computed Tomography Images

Overview

Journal J Bone Miner Metab

Specialty Endocrinology

Date 2024 Jan 9

PMID 38194089

Authors

Yuka Kojima

Shunsuke Sawada

Yuki Sakamoto

Affiliations

Soon will be listed here.

Abstract

Introduction: Surgery is the standard treatment for medication-related osteonecrosis of the jaw (MRONJ). This study reviewed patients with mandibular MRONJ who underwent surgical treatment, and in particular the characteristics of non-osteolytic MRONJ with no evidence of osteolysis on CT were described.

Materials And Methods: We conducted a retrospective study of patients with mandibular MRONJ who underwent surgery between January 2016 and September 2022. Various clinical and imaging factors regarding treatment outcomes were investigated and analyzed. Additionally, the disease course of non-osteolytic MRONJ was examined in detail.

Results: This study included 55 patients (66 surgeries) with a mean age of 74.7. The primary disease was osteoporosis (24 patients) and malignancy (31 patients); the type of antiresorptive agent was bisphosphonate (BP) in 21 patients and denosumab (DMB) in 26. BP was initially administered; however, it was changed to DMB in eight patients. Preoperatively, the cumulative cure rates for all 66 surgeries were 72.8% at 1 year and 77.3% at 2 years. Cure rates were significantly lower in patients with malignancy, those without osteolysis, and those who underwent sequestrum removal or marginal mandibulectomy than those with osteoporosis, osteolysis, and segmental mandibulectomy. Non-osteolytic MRONJ was observed in eight patients, all with malignancy and receiving high-dose DMB. Only two patients were cured after the initial surgery, and most patients ultimately underwent segmental mandibulectomy.

Conclusions: Surgical treatment yielded good treatment outcomes in most patients with mandibular MRONJ; however, the cure rate was lower in patients with malignancy who showed no osteolysis on CT images.

Citing Articles

Application of bone perforation in the surgery of medication-related osteonecrosis of the jaw in stage Ⅱ.

Gao N, Tian M, Sun Y, Wang D, Sun G Hua Xi Kou Qiang Yi Xue Za Zhi. 2024; 42(5):629-635.

PMID: 39304506 PMC: 11493859. DOI: 10.7518/hxkq.2024.2024133.

Postoperative Recurrence of Medication-Related Osteonecrosis of the Jaw: A Retrospective Study of 150 Patients Undergoing Surgery.

Sawada S, Sakamoto Y, Kirihigashi M, Kojima Y Cureus. 2024; 16(6):e62930.

PMID: 39044867 PMC: 11262912. DOI: 10.7759/cureus.62930.

Differences Between Medication-Related Osteonecrosis of the Jaw Caused by Bisphosphonates and Denosumab: Histological, Molecular Biological, and Clinical Studies.

Miyoshi T, Otsuru M, Morishita K, Omori K, Miura K, Hayashida S Cureus. 2024; 16(6):e62855.

PMID: 39036251 PMC: 11260442. DOI: 10.7759/cureus.62855.

Pathogenesis of Medication-Related Osteonecrosis of the Jaw: Odontogenic Infection-Preceding Type and Osteonecrosis-Preceding Type.

Sakamoto Y, Sawada S, Kojima Y Cureus. 2024; 16(5):e60223.

PMID: 38868238 PMC: 11167574. DOI: 10.7759/cureus.60223.

References

Yarom N, Shapiro C, Peterson D, Van Poznak C, Bohlke K, Ruggiero S . Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline. J Clin Oncol. 2019; 37(25):2270-2290. DOI: 10.1200/JCO.19.01186. View

Hayashida S, Soutome S, Yanamoto S, Fujita S, Hasegawa T, Komori T . Evaluation of the Treatment Strategies for Medication-Related Osteonecrosis of the Jaws (MRONJ) and the Factors Affecting Treatment Outcome: A Multicenter Retrospective Study with Propensity Score Matching Analysis. J Bone Miner Res. 2017; 32(10):2022-2029. DOI: 10.1002/jbmr.3191. View

Graziani F, Vescovi P, Campisi G, Favia G, Gabriele M, Gaeta G . Resective surgical approach shows a high performance in the management of advanced cases of bisphosphonate-related osteonecrosis of the jaws: a retrospective survey of 347 cases. J Oral Maxillofac Surg. 2012; 70(11):2501-7. DOI: 10.1016/j.joms.2012.05.019. View

Ruggiero S, Kohn N . Disease Stage and Mode of Therapy Are Important Determinants of Treatment Outcomes for Medication-Related Osteonecrosis of the Jaw. J Oral Maxillofac Surg. 2015; 73(12 Suppl):S94-S100. DOI: 10.1016/j.joms.2015.09.024. View

Kim H, Lee S, Kim S, Myoung H, Hwang S, Choi J . Extensive Surgical Procedures Result in Better Treatment Outcomes for Bisphosphonate-Related Osteonecrosis of the Jaw in Patients With Osteoporosis. J Oral Maxillofac Surg. 2017; 75(7):1404-1413. DOI: 10.1016/j.joms.2016.12.014. View

Mucke T, Koschinski J, Deppe H, Wagenpfeil S, Pautke C, Mitchell D . Outcome of treatment and parameters influencing recurrence in patients with bisphosphonate-related osteonecrosis of the jaws. J Cancer Res Clin Oncol. 2010; 137(5):907-13. DOI: 10.1007/s00432-010-0953-1. View

Ruggiero S, Dodson T, Aghaloo T, Carlson E, Ward B, Kademani D . American Association of Oral and Maxillofacial Surgeons' Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update. J Oral Maxillofac Surg. 2022; 80(5):920-943. DOI: 10.1016/j.joms.2022.02.008. View

Kojima Y, Kawaoka Y, Sawada S, Hayashida S, Okuyama K, Yutori H . Clinical significance of periosteal reaction as a predictive factor for treatment outcome of medication-related osteonecrosis of the jaw. J Bone Miner Metab. 2019; 37(5):913-919. DOI: 10.1007/s00774-019-00994-1. View

Kojima Y, Soutome S, Otsuru M, Hayashida S, Sakamoto Y, Sawada S . Factors Exacerbating Clinical Symptoms and CT Findings in Patients with Medication-Related Osteonecrosis of the Jaw Receiving Conservative Therapy: A Multicenter Retrospective Study of 53 Cases. Int J Environ Res Public Health. 2022; 19(13). PMC: 9265462. DOI: 10.3390/ijerph19137854. View

10.

Soutome S, Yanamoto S, Sumi M, Hayashida S, Kojima Y, Sawada S . Effect of periosteal reaction in medication-related osteonecrosis of the jaw on treatment outcome after surgery. J Bone Miner Metab. 2020; 39(2):302-310. DOI: 10.1007/s00774-020-01154-6. View

11.

Soutome S, Otsuru M, Hayashida S, Yanamoto S, Sasaki M, Takagi Y . Periosteal reaction of medication-related osteonecrosis of the jaw (MRONJ): clinical significance and changes during conservative therapy. Support Care Cancer. 2021; 29(11):6361-6368. DOI: 10.1007/s00520-021-06214-9. View

12.

Rupel K, Ottaviani G, Gobbo M, Contardo L, Tirelli G, Vescovi P . A systematic review of therapeutical approaches in bisphosphonates-related osteonecrosis of the jaw (BRONJ). Oral Oncol. 2014; 50(11):1049-57. DOI: 10.1016/j.oraloncology.2014.08.016. View

13.

Fliefel R, Troltzsch M, Kuhnisch J, Ehrenfeld M, Otto S . Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review. Int J Oral Maxillofac Surg. 2015; 44(5):568-85. DOI: 10.1016/j.ijom.2015.01.026. View

14.

Bisdas S, Chambron Pinho N, Smolarz A, Sader R, Vogl T, Mack M . Biphosphonate-induced osteonecrosis of the jaws: CT and MRI spectrum of findings in 32 patients. Clin Radiol. 2007; 63(1):71-7. DOI: 10.1016/j.crad.2007.04.023. View

15.

Wongratwanich P, Shimabukuro K, Konishi M, Nagasaki T, Ohtsuka M, Suei Y . Do various imaging modalities provide potential early detection and diagnosis of medication-related osteonecrosis of the jaw? A review. Dentomaxillofac Radiol. 2021; 50(6):20200417. PMC: 8404513. DOI: 10.1259/dmfr.20200417. View

16.

Lipton A, Fizazi K, Stopeck A, Henry D, Brown J, Yardley D . Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer. 2012; 48(16):3082-92. DOI: 10.1016/j.ejca.2012.08.002. View

17.

Weinstein R, Roberson P, Manolagas S . Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med. 2009; 360(1):53-62. PMC: 2866022. DOI: 10.1056/NEJMoa0802633. View

18.

Kopper L . Denosumab--a powerful RANKL inhibitor to stop lytic metastases and other bone loss actions by osteoclasts. Pathol Oncol Res. 2012; 18(4):743-7. DOI: 10.1007/s12253-012-9538-4. View

19.

Baba A, Ojiri H, Goto T, Ikeda K, Yamauchi H, Ogino N . Symposium: Imaging modalities for drug-related osteonecrosis of the jaw (4), CT and MR imaging findings of antiresorptive agent-related osteonecrosis of the jaws/medication-related osteonecrosis of the jaw (secondary publication). Jpn Dent Sci Rev. 2019; 55(1):58-64. PMC: 6378898. DOI: 10.1016/j.jdsr.2018.11.001. View

20.

Moridera K, Kitajima K, Yoshikawa K, Takaoka K, Tsuchitani T, Noguchi K . Usefulness of quantitative bone SPECT/CT for medication-related osteonecrosis of the jaw in clinical settings. Jpn J Radiol. 2021; 40(5):492-499. DOI: 10.1007/s11604-021-01226-1. View